Navigation Links
Immune Design Grants Adjuvant License to MedImmune
Date:10/26/2010

SEATTLE, Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

"We are pleased to enter into this license with MedImmune as one of the world's leading vaccine research-based pharmaceutical and healthcare companies," commented IDC Executive Chairman Dr. Bruce Carter.  "This relationship fits very well with IDC’s business model to advance the development of GLA and enable innovative vaccine products that we believe will provide significant benefit in areas of unmet need while maintaining our commitment to global access."

Under the terms of the license agreement, IDC grants MedImmune exclusive worldwide rights to research, develop, use, and commercialize the GLA adjuvant in vaccines for specific indications.  In return, IDC will receive an upfront licensing fee and potential development, regulatory and commercial milestones totaling $212M, in addition to royalty payments on sales of marketed products.  

GLA is a toll-like receptor 4 (TLR-4) agonist which IDC has advanced into early clinical stage development.  The small molecule adjuvant has several important features including a pure synthetic composition with straightforward manufacturing and long term stability, a rational design for optimal activation of human dendritic cells, compatibility with antigens in multiple formulations, and a well established safety profile.  

About Immune Design Corp.: Immune Design Corp. is a privately held biotechnology company based in Seattle, WA.  IDC brings together some of the world’s leaders in the field of molecular immunology to develop vaccines for the prevention and treatment of infectious and malignant disease.  The company employs leading edge technologies to target and activate dendritic cells for effective antigen presentation to direct the desired immune response.  For more information, go to www.immunedesign.com.  

About MedImmune:MedImmune, the worldwide biologics unit for AstraZeneca PLC (NYSE: AZN; LSE: AZN.L), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.Media Relations: Immune Design Corp. Cassie D. Ostrander (206) 826-7901media@immunedesign.com
'/>"/>

SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding into ... a broad range of contract analysis services for advanced applications. Services will ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
Breaking Biology Technology:
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):